

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol						bol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
PETERS WILLIAM J					Amphastar Pharmaceuticals, Inc. [AMPH]						.[Director	,	10%	Owner	
(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)						Y)	X_ Officer (give title below) Other (specify below) CFO, EVP & Treasurer					
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET					7/7/2021											
(Street)					4. If Amendment, Date Original Filed (MM/DD/YYYY)						DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)				
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)									X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
			Table I	I - Non-l	Deriva	ative S	ecurities A	cqui	ired, D	isposed	of, or Bei	neficially Owne	ed			
1. Title of Security (Instr. 3) 2. Trans. Da			e 2A. Deemed Execution Date, if any		3. Trans. Code (Instr. 8)		4. Securities Acquire Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ownership Form:	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price					(Instr. 4)
Common Stock 7/7/2021						M		10000	A	\$11.33	122278 (1) D					
Common Stock 7/7/2021						S ⁽²⁾		10000	D S	620.3739 ⁽²⁾	112278			D		
	Tab	ole II - Der	ivative	Securit	ies Be	neficia	ally Owned	(e.g	, puts	, calls, w	arrants,	options, conver	tible secu	ırities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deer Execution Date, if a		Derivat Acquire Dispose		mber of ative Securities red (A) or sed of (D) 3, 4 and 5)		6. Date Exercisable and Expiration Date			Underlying Security Security (Instr. 5)		derivative Securities Beneficially Owned	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Co	de V	7 (A)	(D)	Dat Exe	e ercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Employee Stock Option (right to buy)	\$11.33	7/7/2021		М			10000		<u>(3)</u>	3/17/2026	Common Stock	10000	\$0	29800	D	

Explanation of Responses:

- (1) Includes 929 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2021.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$20.33 to \$20.465, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- (3) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
PETERS WILLIAM J C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730			CFO, EVP & Treasurer			

Signatures

/s/ William J. Peters	7/8/2021
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.